Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 2Wilms Tumor 1Sarcoma 1Ovarian Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × tariquidar × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

NCT00001944 2008-03-04

Vinorelbine and XR9576 to Treat Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡